Antibiotics, such as Amoxicillin, are extremely effectual when used appropriately prior to surgical procedures. The expiration of the potent antimicrobial drug Moxatag, also known as Amoxicillin, on October 13, 2020, paves the way for additional development of this generic powerhouse. Study results recently released in Infection Control and Hospital Epidemiology reveal that timing is[…]
Amoxicillin Effective When Timed Optimally Before Surgery
Antibiotic, Drug Research & Development API, Patent Expiration 2020, TEVA API Tags: antibiotic Aug 18, 2014
Anti-Smoking Therapy Varenicline Tartrate Still Best Option
Drug Research & Development API, Patent Expiration 2020 Apr 29, 2014
Recent study data revealed from the Mayo Clinic in Rochester, Minnesota reaffirmed the efficacy and tolerability of Varenicline for helping patients stop smoking. Known as the brand name Chantix, which has a patent expiration of May 10, 2020, the drug Varenicline has been proven to be successful as a single agent. On January 15, 2014[…]
Regorafenib Proves to Show Additional Benefits
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Patent Expiration 2020 Tags: EUregorafenib Apr 28, 2014
Regorafenib is a formidable treatment for colon cancer, and in late 2013 it has received another new approval for GIST in Japan and Europe. Known as the trade name Stivarga, Regorafenib was approved in both Japan and Europe for the treatment of gastrointestinal stromal tumors. The FDA approved Regorafenib two years ago and added the[…]
2014 Study Reveals Rosuvastatin Calcium Most Effectual Post Heart Attack
OTC and Compounding Product, Patent Expiration 2020 Mar 04, 2014
Rosuvastatin Calcium, known as the brand name Crestor, has a patent expiration of August 4, 2020. Recent study data revealed that patients who received the high potency statin Rosuvastatin after a heart attack had a high survival rate. This study from the Cardiovascular division at the University of Dundee Medical School compared Ezetimibe with higher[…]
Fenofibrate Safe for Patients with Type 2 Diabetes
Cardiovascular Agent, Drug Research & Development API, Patent Expiration 2015, Patent Expiration 2018, Patent Expiration 2020 Tags: HDLLDL Aug 15, 2012
Fenofibrate, CAS number 49562-28-9, is known as the brand name Lipofen, which is marketed by Cipher-Kowa Pharmaceuticals. The patent for Lipofen is due to expire on January 10, 2015. Other recognizable brands of fenofibrate are Tricor, which has a patent expiration of January 9, 2018 and Antara, which has a patent expiration set for August[…]
